Neurol. pro Praxi, 2004; 3: 155-159

Psychofarmakoterapie psychických komplikací Parkinsonovy nemoci

MUDr. Jiří Masopust1, MUDr. Martin Vališ2
1 Psychiatrická klinika LF UK a FN Hradec Králové
2 Neurologická klinika LF UK a FN v Hradci Králové

Keywords: Parkinsonova nemoc, psychické komplikace, psychofarmaka, extrapyramidové vedlejší účinky.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J, Vališ M. Psychofarmakoterapie psychických komplikací Parkinsonovy nemoci. Neurol. praxi. 2004;7(3):155-159.

Péče o pacienty s Parkinsonovou nemocí vyžaduje interdisciplinární přístup neurologů a psychiatrů. Popisujeme základní charakteristiky nejčastěji se vyskytujících psychických komplikací Parkinsonovy nemoci. Tyto často nejsou rozpoznány a nebo jsou nesprávně léčeny. Při výběru psychofarmaka musíme brát v úvahu věk a somatický stav nemocného, riziko lékových interakcí a možný vliv daného léku na zhoršení motorických příznaků Parkinsonovy nemoci. Podáváme souhrn nejvhodnějších preparátů k léčbě psychických komplikací podle literatury i klinických zkušeností.

Psychiatrická klinika LF UK a FN Hradec Králové

Neurologická klinika LF UK a FN Hradec Králové

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000; 320: 1287-1288. Go to original source... Go to PubMed...
    2. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107-110. Go to original source... Go to PubMed...
    3. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 258-264. Go to original source... Go to PubMed...
    4. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003; 18 (Suppl 6): S72-79. Go to original source... Go to PubMed...
    5. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65. Go to original source... Go to PubMed...
    6. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-211. Go to original source... Go to PubMed...
    7. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 748-749. Go to original source... Go to PubMed...
    8. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14: 461-462. Go to original source... Go to PubMed...
    9. Jost WH, Brück C. Drug interactions in the treatment of Parkinson's disease. J Neurol 2002; 249 (Suppl 3): 24-29. Go to original source... Go to PubMed...
    10. Korczyn AD. Hallucinations in Parkinson's disease. Lancet 2001; 358: 1031-1032. Go to original source... Go to PubMed...
    11. Marsh L. Neuropsychiatric aspects of Parkinson's disease. Psychosomatics 2000; 41: 15-23. Go to original source... Go to PubMed...
    12. Pidrman V. První zkušenosti s užitím blokátorů zpětného vychytávání noradrenalinu a dopaminu v léčbě deprese. Psychiatrie pro praxi 2002; 3: 35-37.
    13. Poewe W. Psychosis in Parkinson's disease. Mov Disord 2003; 18 (Suppl 6): S80-87. Go to original source... Go to PubMed...
    14. Rektor I, Rektorová I et al. Centrální poruchy hybnosti v praxi. Movement disorders. Praha: Triton 2003; 196.
    15. Rektorová I, Rektor I, Bareš M, Dostál V, Ehler E, Fanfrdlová Z, Fiedler J, Klajblová H, Kulišťák P, Ressner P, Svátová J, Urbánek K, Velísková J. Pramipexole and pergolide in the tretment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406. Go to original source... Go to PubMed...
    16. Růžička E, Roth J, Kaňovský P et al. Parkinsonova nemoc a parkinsonské syndromy. Praha: Galén 2000; 290.
    17. Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness. Eur Neurol 2003; 49: 30-33. Go to original source... Go to PubMed...
    18. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 187-196. Go to original source... Go to PubMed...
    19. Taylor D, McConnell H, McConnell D et al. The Maudsley Prescribing guidelines. 6th ed. London: Martin Dunitz Ltd 2001; 221.
    20. Wijnen HH, van der Heijden FMMA, van Schendel FME, Tuinier S, Verhoven WMA. Quetiapine in the elderly with parkinsonism and psychosis. Eur Psychiatry 2003; 18: 372-373. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.